Twist Bioscience Corporation
TWST
Pozycja w akcjach
#2194
Twist Bioscience Corporation operates as a leading synthetic biology firm,... Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Cena akcji
$140.67
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$9.26B
Zmiana (1 dzień)
5.97%
Zmiana (1 rok)
329.66%
Kraj
US
Handel Twist Bioscience Corporation (TWST)
Kategoria
Healthcare
Zyski dla Twist Bioscience Corporation (TWST)
Zyski w Jun 2026 TTM: $-135.85M
Według najnowszych raportów finansowych Twist Bioscience Corporation, obecny zysk firmy wynosi $-135.85M. W roku 2024 firma osiągnęła zysk w wysokości $-208.17M, spadek w porównaniu do zysku z roku 2023, który wynosił $-203.47M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Twist Bioscience Corporation od 2016 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $-135.85M | 76.55% |
| 2025 | $-76.95M | -63.03% |
| 2024 | $-208.17M | 2.31% |
| 2023 | $-203.47M | -10.87% |
| 2022 | $-228.27M | 48.20% |
| 2021 | $-154.03M | 10.38% |
| 2020 | $-139.55M | 29.96% |
| 2019 | $-107.38M | 51.25% |
| 2018 | $-70.99M | 20.27% |
| 2017 | $-59.03M | 33.89% |
| 2016 | $-44.09M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $7.61B | -5,700.87% |
US
|
|
| $4.76B | -3,605.23% |
US
|
|
| $-252.70M | 86.01% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -1,320.43% |
US
|
